Evidence map›Paper›PMID 36898724›Full record

ArticlePhysiological reports2023

Characterization of acute lung injury in the bleomycin rat model.

Anil Hari Kadam, Jan E Schnitzer

Open access · goldFull text read
In one paragraph

Article in Physiological reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Protective Role of Octreotide in Acute and Chronic Lung Injuries.International journal of preventive medicine · 2026
    Article
  4. Dose-dependent protective effects ofFrontiers in pharmacology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. An overview of CCN4 (WISP1) role in human diseases.Journal of translational medicine · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anil Hari KadamProteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, USA.ORCID 0000-0001-5897-8413
Jan E SchnitzerProteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, USA.ORCID 0000-0001-8211-9539
Proteogenomics Research Institute for Systems Medicine · US

Funding

Targeting TGF-b Inhibitors and PPAR-y Agonists To Enhance IPF TherapyP01HL119165 · NHLBI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI SCHNITZER, JAN EUGENIUSZ · 2015 to 2019
$13.6M
NHLBI NIH HHS P01 HL119165
6 · The paper itself

Abstract

The aim of this study was to describe and characterize the pathophysiological changes occurring during the early inflammatory phase (first 3 days) in the rat bleomycin model of lung injury preceding the development of fibrosis. Further, we wanted to understand the kinetics and factors contributing to bleomycin-induced acute lung injury (ALI) and provide a robust, reliable and reproducible framework of features of ALI readouts to assess effects of therapeutics on bleomycin-induced ALI in rats. We induced ALI in rats with intratracheal (i.t.) installation of bleomycin. The animals were sacrificed on predetermined time points, that is, Day 0, 1, 2, and 3 post the bleomycin challenge. We analyzed bronchoalveolar lavage fluid (BALF) and lung tissue to establish and assess relevant experimental features of ALI. We demonstrated that bleomycin induced key features of experimental ALI including a profound increase in neutrophils in BALF (50-60%), pulmonary edema, and lung pathology on Day 3 after challenge. Furthermore, we showed that TGF-β1, IL-1β, TNF-α, IL-6, CINC-1, TIMP-1, and WISP-1 were induced by studying their kinetic profile during the first 3 days after bleomycin injury consistent with their known role ALI. We also confirmed that detectable fibrogenesis occurs at the earliest on Day 3 after injury based on collagen content, along with changes in the TGF-β/Smad signaling pathway and increased expression of Galectin-3, Vimentin, and Fibronectin in lung homogenate. Our report presents robust features and contributing mediators/factors to the pathology of bleomycin-induced ALI in rats on Day 3. The kinetic data provide insights on the progression of ALI and a detailed understanding of early events before actual fibrosis development. This set of experimental endpoints is very appropriate and invaluable for efficacy testing of potential novel therapeutic treatments (single or combined) in ALI and understanding their mechanism of action.

Indexed as

Acute Lung InjuryPulmonary FibrosisAnimalsBleomycinBronchoalveolar Lavage FluidFibrosisLungRatsBleomycinacute lung injury (ALI)bleomycinbronchoalveolar lavage fluid (BALF)contributing mediators/factorsdetectable fibrogenesisefficacy testingexperimental endpointskey experimental features of ALImechanism of actionneutrophilic inflammationprogression of bleomycin-induced ALI

Identifiers

PMID36898724
PMCPMC10005890
OpenAlexW4323830779

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read41
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.